Mortality of Patients Infected by COVID-19 with and without Deep-Vein Thrombosis

Background: Current evidence points to a state of hypercoagulability (consequence of hyperinflammation) as an important pathogenic mechanism that contributes to the increase in mortality in cases of COVID-19. The aim of the present study was to investigate the influence of deep-vein thrombosis on mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira de Godoy, Jose Maria, Russeff, Gleison Juliano da Silva, Costa, Carolina Hungaro, Sato, Debora Yuri, Silva, Desirée Franccini Del Frari, Guerreiro Godoy, Maria de Fatima, Pereira de Godoy, Henrique Jose, Espada, Paulo César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708913/
https://www.ncbi.nlm.nih.gov/pubmed/34940287
http://dx.doi.org/10.3390/medicines8120075
Descripción
Sumario:Background: Current evidence points to a state of hypercoagulability (consequence of hyperinflammation) as an important pathogenic mechanism that contributes to the increase in mortality in cases of COVID-19. The aim of the present study was to investigate the influence of deep-vein thrombosis on mortality patient’s infected with SARS-CoV-2. Method: A clinical trial was conducted involving 200 consecutive patients with COVID-19—100 patients who were positive for deep-vein thrombosis (venous Doppler ultrasound) and 100 who were negative for deep-vein thrombosis at a public hospital. Results: The mortality rate was 67% in the group positive for DVT and 31% in the group negative for DVT. Conclusion: Deep-vein thrombosis is associated with an increase in mortality in patients with COVID-19 and failures can occur with conventional prophylaxis for deep-vein thrombosis.

Ejemplares similares